An ADC that targets increased expression in advanced lesions of a biomarker like PTGFRN in mesothelioma would be an invaluable tool to develop new treatments for patients suffering from these advanced‐stage cancers, along with the availability of a biomarker to identify patients [43]. The gene discussed is PTGFRN; the disease is cancer.